These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10604262)

  • 1. Docetaxel (Taxotere): preclinical and general clinical information.
    Earhart RH
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
    Friedland D; Cohen J; Miller R; Voloshin M; Gluckman R; Lembersky B; Zidar B; Keating M; Reilly N; Dimitt B
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):19-23. PubMed ID: 10604264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
    Vogelzang NJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
    [No Abstract]   [Full Text] [Related]  

  • 5. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of taxanes in prostate cancer.
    Stein CA
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):3-7. PubMed ID: 10604261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-68. PubMed ID: 10610580
    [No Abstract]   [Full Text] [Related]  

  • 9. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
    Kreis W; Budman D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical rationale for developing docetaxel (Taxotere).
    Armand JP
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) in the treatment of cancer.
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (taxotere, Rhone-Poulenc Rorer).
    MacConnachie AM
    Intensive Crit Care Nurs; 1997 Apr; 13(2):119-20. PubMed ID: 9180501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
    Rowinsky EK
    Annu Rev Med; 1997; 48():353-74. PubMed ID: 9046968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.